Company Performance Metrics
OncoGenomX, a Swiss company founded by Wolfgang Hackl and David Demanse, develops treatment guidance software. Its first product, PredictionStar, helps breast cancer doctors in determining the optimal treatment for lasting metastasis prevention.
AI-enabled treatment – tumor pairing validated by real-world outcome evidence sustains an 85% chance
of determining the best treatment option. This outperforms clinical decision offerings of the competition (55% chance).
Complementing digital genomics by digital clinical and histological image analysis accelerates the clinical decision process, facilitates an earlier treatment start, and shortens the time of uncontrolled tumor growth.
OncoGenomX augments and extends the decision support that hospital-based cancer test laboratories provide to oncologists. By empowering oncologists with information from the best tumor - treatment matching tool, PredictionStar effectively reduces the risks of over or under-treatment, maximizes treatment efficiency, and diminishes costs.
Our core competency: • Analysis and interpretation of digital clinical images, digital histology images, tumor and blood gene testing results to predict pharmacological weak points. • Custom cancer treatments targeting the Achilles Heel of any given tumor. • Provision of recent real-world outcome evidence on comparable tumors to validate imputed tumor – treatment pairings. • Tailor-made clinical decision guidance – predictive, reliable, clinically actionable.
Our vision: Omission of randomness and uncertainty from clinical decision support and cancer therapy decisions.
Our mission: To become the best treatment guidance software and to make durable metastasis prevention an option and a reality for all patients.
Working closely with the key stakeholders of breast cancer care, OncogenomX is committed to game-changing software innovations - For value-based care, longer, healthier, and better lives of women with breast cancer.
